300970 Jiangsu Chinagreen Biological Technology
- 13.50
- -0.40-2.88%
Jiangsu Chinagreen Biological Technology News
Hualu Biotech (300970.SZ): A total cost of 30.46 million yuan to repurchase 2,346,600 shares
Gelonghui, May 31, 丨 Hualu Biotech (300970.SZ) announced that as of May 31, 2024, the company was repurchasing 2,346,600 shares through the Shenzhen Stock Exchange stock trading system, accounting for 1.99% of the company's current total share capital. The highest transaction price was 13.83 yuan/share, the minimum transaction price was 12.22 yuan/share, and the total transaction amount was RMB 30.46 million (excluding transaction fees).
Hualu Biotech (300970.SZ) 2023 equity distribution: 2 yuan for every 10 shares
According to Zhitong Finance App, Hualu Biotech (300970.SZ) announced that the company's 2023 equity distribution plan is to distribute 2 yuan in cash (tax included) to all shareholders for every 10 shares. The share registration date for this equity distribution is: June 3, 2024, and the ex-dividend date is June 4, 2024.
Agricultural stocks fluctuated and declined. Shennong Technology fell more than 8%, followed by Oriental Group, Xingguang Agricultural Machinery, Jin Zhengda, Hualu Biotech, and Xuerong Biotech.
Agricultural stocks fluctuated and declined. Shennong Technology fell more than 8%, followed by Oriental Group, Xingguang Agricultural Machinery, Jin Zhengda, Hualu Biotech, and Xuerong Biotech.
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
Hualu Biotech (300970.SZ): Not involved in artificial meat business
Gelonghui, May 13 | Hualu Biotech (300970.SZ) said on the investor interactive platform that the company is not involved in the artificial meat business yet.
Express News | Hualu Biotech: The company has plans to do some early exploration in the field of synthetic biology
Hualu Biotech (300970.SZ): 1.99% of shares have been repurchased
Gelonghui, April 30, 丨 Hualu Biotech (300970.SZ) announced that as of April 30, 2024, the company will repurchase 2,346,600 shares of the company through centralized bidding transactions through the Shenzhen Stock Exchange stock trading system, accounting for 1.99% of the company's current total share capital. The maximum transaction price is 13.83 yuan/share, the minimum transaction price is 12.22 yuan/share, and the total transaction amount is RMB 30.46 million (excluding transaction fees).
Hualu Biotech (300970.SZ): Net profit of 1,7395 million yuan in the first quarter decreased by 98.66% year-on-year
Gelonghui, April 22 | Hualu Biotech (300970.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 257 million yuan, down 22.75% year on year; net profit attributable to shareholders of listed companies was 1,7395 million yuan, down 98.66% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 817,700 yuan, down 99.36% year on year; basic earnings per share were 0.02 yuan.
Express News | Restricted stocks with a market capitalization of 5,018 billion yuan were lifted today. Shangsheng Electronics lifted the ban and ranked first with a market capitalization of 2,912 billion yuan
Hualu Biotech (300970.SZ) will list and circulate 48,135,500 restricted shares on April 19
Zhitong Finance App News, Hualu Biotech (300970.SZ) announced that the number of shares issued by the company before the initial public offering has been lifted is 48.135,500 shares, accounting for 40.8313% of the company's total share capital. The listing circulation date is April 19, 2024 (Friday).
Hualu Biotech (300970.SZ): A total of 1.09% of shares have been repurchased
Gelonghui, March 12, 丨 Hualu Biotech (300970.SZ) announced that as of March 11, 2024, the company had repurchased 1,287,900 shares through the Shenzhen Stock Exchange stock trading system, accounting for 1.09% of the company's current total share capital. The highest transaction price was 12.70 yuan/share, the minimum transaction price was 12.22 yuan/share, and the total transaction amount was RMB 160,996.19 million (not including transaction fees).
Hualu Biotech (300970.SZ): Initial repurchase of 0.34% of shares
Gelonghui, March 8, 丨 Hualu Biotech (300970.SZ) announced that on March 7, 2024, the company repurchased 400,300 shares of the company's shares for the first time through the Shenzhen Stock Exchange stock trading system, accounting for 0.34% of the company's current total share capital. The highest transaction price was 12.59 yuan/share, the lowest transaction price was 12.35 yuan/share, and the total transaction amount was RMB 4,997,860.00.
Express News | Fourteen listed companies disclosed repurchase plans after the market and announced that Guojin Securities plans to repurchase up to 100 million yuan and use it to reduce registered capital
Express News | Hualu Biotech: Chairman proposes 30 million yuan to 60 million yuan to repurchase shares
Hualu Biotech (300970.SZ): 2023 net profit pre-reduced by 51.44%-61.66%
Gelonghui, January 26 | Hualu Biotech (300970.SZ) announced its 2023 annual results forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 300.00-380.00 million yuan, down 51.44%-61.66% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 300.00-380.00 million yuan, a decrease of 40.52% to -53.04% over the same period last year. Affected by the overall market conditions of vegetables and edible fungi during the reporting period, the overall sales price of enoki mushrooms decreased a lot compared to the same period in previous years; the company
The majority shareholder of Hualu Biotech (300970.SZ) reduced its holdings by 1.3996 million shares at the end of the reduction period
Hualu Biotech (300970.SZ) announced that Jiangsu Gaotou Development Venture Capital Co., Ltd., the shareholder of the company holds more than 5% of the shares...
Hualu Biotech (300970. SZ): The 54,000-ton enoki mushroom project is currently in the trial production stage
Gelonghui November 8: Some investors asked Hualu Biotech (300970.SZ) on the investor interactive platform, “May I ask what stage the company's 54,000-ton enoki mushroom project is currently in, trial production or mass production climbing, and probably when will it reach full production.” The company replied that the company's 54,000-ton enoki mushroom project is currently in the trial production stage, so please pay attention to the relevant announcements at that time.
Hualu Biotech (300970.SZ): Net loss of 31.3647 million yuan in the third quarter
Glonghui, Oct. 26丨Hualu Biotech (300970.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 223 million yuan, down 4.44% from the previous year; net profit attributable to shareholders of listed companies - 31.3647 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 31.3758 million yuan; basic earnings per share - 0.2688 yuan.
Hualu Biotech (300970.SZ) plans to jointly build an organic fertilizer production base with Sviber to promote the development of the agricultural circular economy
Hualu Biology (300970.SZ) announced that the company and Jiangsu Siweibo Biotechnology Co., Ltd. (“Siweibo”)...
3707 companies announced semi-annual reports, 450 companies doubled their performance
GLONGHUI, August 29 | According to the Securities Times, as of August 29, 3,707 companies have published their 2023 semi-annual reports. Among them, 1993 had a year-on-year increase in net profit, 1,714 had a year-on-year increase, 2,225 had a year-on-year increase in revenue, 1,480 had a year-on-year increase in revenue, 1,612 companies, including Hualu Biotech, etc., and 1101 companies, including Weilong Co., Ltd., where profit and revenue all declined. There were 450 companies that doubled their performance.
Analysis
Price Target
No Data
